Analysts who follow Mersana Therapeutics Inc (MRSN) on average expect it to decline -13.48% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns the stock an Analyst Ranking of 18, which means it ranks higher than 18 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating MRSN a Buy today. Find out what this means to you and get the rest of the rankings on MRSN!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Mersana Therapeutics Inc Stock Today?
Mersana Therapeutics Inc (MRSN) stock is trading at $6.01 as of 12:42 PM on Friday, Mar 1, a rise of $0.57, or 10.48% from the previous closing price of $5.44. The stock has traded between $5.50 and $6.19 so far today. Volume today is low. So far 1,300,358 shares have traded compared to average volume of 2,106,452 shares.
Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
